Human Pharmacokinetics and Metabolism Absorption. PENTASA is an ethylcellulose-coated, controlled-release formulation of mesalamine designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. Based on urinary excretion data, 20% to 30% of the mesalamine in PENTASA
ثبت نشده
چکیده
CLINICAL PHARMACOLOGY Sulfasalazine is split by bacterial action in the colon into sulfapyridine (SP) and mesalamine (5-ASA). It is thought that the mesalamine component is therapeutically active in ulcerative colitis. The usual oral dose of sulfasalazine for active ulcerative colitis in adults is 2 to 4 g per day in divided doses. Four grams of sulfasalazine provide 1.6 g of free mesalamine to the colon.
منابع مشابه
New Dissolution Method for Mesalamine Tablets and Capsules
Dissolution methods are different for extended-release mesalamine capsules (pH 7.5 only) and delayed-release tablets (pH 1.4, 6.0, and 7.2). Mesalamine is used for the treatment of ulcerative colitis. The USP methods have several drawbacks in that they do not mimic gastrointestinal tract environments; tablets are removed from vessels to change dissolution medium; and neither method has been ado...
متن کاملDesign and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System
Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects. The main objective of this work is to attain mesalamine loaded chitosan nanoparticles as a carrier for oral delivery. Methods: In this study, me...
متن کاملNew Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.
6 Gastroenterology & Hepatology Volume 6, Issue 1, Supplement 1 January 2010 Multiple daily dosing of 5-ASA for UC has been a standard practice since the 1940s. However, these regimens can lead to poor patient adherence. Recently, several 5-ASA formulations have demonstrated non-inferiority to multiple daily dosing, including ethylcellulose-coated microgranules (Pentasa),1 Multi-Matrix delayed ...
متن کاملRelease of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
INTRODUCTION Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically relevant pH conditions. METHODS Release of 5-ASA from 6 mesalamine formulations (APRISO®, Salix Phar...
متن کاملGastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dyn...
متن کامل